In that study, OV delivery and tumor cell killing resulted in generation of CD8+ CTL responses against the dominant “tumor-specific” major histocompatibility complex (MHC) class I-restricted epitope (AH1) from the Gp70 antigen expressed by CT26 colon cancer cells [50]. The gene discussed is CD8A; the disease is neoplasm.